Patients whose tumor demonstrate bcl-2 positivity even with locoregionally advanced disease, appear to have a high likelihood of cure with aggressive combined modality therapy and may be treated successfully with less toxic therapy. This evidence concerns the gene BCL2 and neoplasm.